Targeted therapy for IDH1-mutated AML is available, and an association between residual IDH1 mutations and post-transplant clinical outcomes may help provide evidence regarding post-alloHCT maintenance approaches [22–25]. Here, IDH1 is linked to acute myeloid leukemia.